OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Parrondo on the Current Treatment Landscape of MCL

October 23rd 2023

Ricardo D. Parrondo, MD, discusses the current treatment landscape of mantle cell lymphoma and highlights ongoing areas of investigation in other hematologic malignancies.

Dr Cho on First-Line Amivantamab Plus Lazertinib in EGFR-Mutant NSCLC

October 23rd 2023

Byoung Chul Cho, MD, PhD, discusses key findings from the phase 3 MARIPOSA study of first-line amivantamab plus lazertinib vs osimertinib in EGFR-mutant locally advanced or metastatic non– small cell lung cancer.

Dr Pietrantonio on the CodeBreak 300 Trial in KRAS G12C-mutated mCRC

October 22nd 2023

Filippo Pietrantonio, MD, discusses the influence of primary results from the phase 3 CodeBreak 300 trial of sotorasib plus panitumumab on KRAS G12C-mutated metastatic colorectal cancer.

Dr Chi on the MAGNITUDE Trial of Niraparib Plus Abiraterone in BRCA-Mutated mCRPC

October 22nd 2023

Kim N. Chi, MD, FRCPC, discusses data from the updated and final analysis of the phase 3 MAGNITUDE trial in BRCA-positive metastatic castration-resistant prostate cancer.

Dr Girard on the Efficacy of First-Line Amivantamab Plus Chemotherapy in EGFR Exon 20 Insertion+ NSCLC

October 21st 2023

Nicolas Girard, MD, PhD, discusses primary efficacy results from the phase 3 PAPILLON trial of amivantamab plus chemotherapy in EGFR exon 20 insertion–mutated advanced non–small cell lung cancer.

Dr Westin on Durvalumab and Chemotherapy With or Without Maintenance Olaparib in Endometrial Cancer

October 21st 2023

Shannon N. Westin, MD, MPH, FACOG, discusses key data on the use of durvalumab plus chemotherapy followed by durvalumab and olaparib maintenance in the phase 3 DUO-E trial of patients with newly diagnosed advanced or recurrent endometrial cancer.

Dr Hammers on a Case Presentation in Advanced RCC

October 21st 2023

Hans Hammers, MD, PhD, discusses a case presentation of a patient with advanced renal cell carcinoma.

Dr Mastroyannis on the Continued Investigation of Targeted Therapies in Ovarian Cancer

October 21st 2023

S. Alex Mastroyannis, MD, MSCE, discusses the management of gynecologic cancers, such as metastatic or recurrent ovarian and endometrial cancers.

Dr Esteva on the Impact of the MAINTAIN Trial in HR+/HER2– Breast Cancer

October 21st 2023

Francisco J. Esteva, MD, PhD, discusses the impact of the phase 2 MAINTAIN study of treatment with ribociclib following progression on CDK4/6 inhibition in patients with hormone receptor-positive, HER2-negative breast cancer.

Dr Kuykendall on Frontline Cytoreductive Therapies in Polycythemia Vera

October 21st 2023

Andrew Kuykendall, MD, discusses frontline cytoreductive treatment options for patients with polycythemia vera.

Dr Pagliaro on the Use of First-Line Avelumab Maintenance Therapy in Urothelial Carcinoma

October 20th 2023

Lance C. Pagliaro, MD, discusses the efficacy of first-line avelumab maintenance therapy, as seen in the phase 3 JAVELIN Bladder 100 trial in patients with advanced urothelial carcinoma.

Dr Bilusic on Updates to the Urothelial Carcinoma Treatment Armamentarium

October 20th 2023

Marijo Bilusic, MD, PhD, discusses updates seen in the treatment armamentarium for patients with urothelial carcinoma, as presented at the 2023 Sylvester Annual Oncology Updates Meeting.

Dr Moustafa on the Evolution of Treatment Options for Patients With MCL

October 20th 2023

Muhamad Alhaj Moustafa, MD, MS, discusses the evolution of treatment options for patients with mantle cell lymphoma.

Dr Zhou on Ongoing Investigations into the Treatment of Patients With Myelofibrosis and Anemia

October 20th 2023

Amy W. Zhou, MD, discusses ongoing and planned trials that may enhance therapeutic options for patients with myelofibrosis and anemia that are currently taking place at the Washington University School of Medicine in St. Louis.

Dr Ahmed on a Study of Real-World Outcomes With Brexu-Cel in Relapsed/Refractory MCL

October 19th 2023

Nausheen Ahmed, MD, discusses the rationale and design of a subgroup analysis of real-world outcomes with brexucabtagene autoleucel in patients with relapsed/refractory mantle cell lymphoma.

Dr Lin on Findings From the CARTITUDE-1 Trial in Relapsed/Refractory Multiple Myeloma

October 19th 2023

Yi Lin, MD, PhD, discusses findings from the primary analysis of the phase 1/2 CARTITUDE-1 trial of the BCMA-targeting CAR T-cell therapy ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.

Dr Bekaii-Saab on Treatment Evolutions in KRAS G12C–Mutant and HER2-Overexpressing CRC

October 18th 2023

Tanios Bekaii-Saab, MD, FACP, discusses the evolution of treatment for patients with KRAS G12C–mutant and HER2-overexpressing colorectal cancer.

Dr Vose on the SYMPHONY-1 Trial in Relapsed/Refractory Follicular Lymphoma

October 18th 2023

Julie M. Vose, MD, MBA, discusses the investigation of tazemetostat vs placebo when given in combination with lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma in the phase 3 SYMPHONY-1 study.

Dr Yentz on Treatment Decisions in Favorable-Risk RCC

October 18th 2023

Sarah Elizabeth Yentz, MD, discusses treatment considerations in patients with favorable-risk renal cell carcinoma.

Dr Berdeja on Patient Factors That Drive Treatment Decisions in Multiple Myeloma

October 18th 2023

Jesus Berdeja, MD, discusses factors to consider when choosing between CAR T-cell therapy and bispecific antibodies in patients with multiple myeloma.